Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-40
SponsorUniversity of Veterinary and Animal Sciences, Lahore - Pakistan

About this trial

This randomized controlled trial aims to evaluate the effect of oral vitamin D3 supplementation on inflammatory biomarkers and disease activity in Pakistani patients with moderate ulcerative colitis. Sixty patients will be randomized to receive either standard treatment alone/Placebo or standard treatment plus vitamin D3 (50,000 IU fortnightly) for 12 weeks. Primary outcomes include changes in blood (CRP, ESR, IL-6) and fecal (calprotectin) inflammatory biomarkers, and disease activity assessed by the partial Mayo score. Secondary outcomes include vitamin D status, dietary intake, and quality of life. The study will provide insights into the immune-modulating and anti-inflammatory role of vitamin D3 as an adjunct therapy in ulcerative colitis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

• All patients diagnosed previously by standard clinical i.e Truelove and Witts and endoscopic/ colonoscopic criteria

Patients with moderate ulcerative colitis will be included

Both male and female patients will be included in the study

No change in the type and dosage of their medicine over the past month

Disqualifiers

Patients suffering from Crohn's disease or any known autoimmune disease

Patients with mild and severe ulcerative colitis

Changes in the type and dosage of the drug during the study

Pregnant and lactating women

Trial design

Design model

Parallel

Treatments tested in this trial

  • Vitamin D3

    Drug

    This intervention consists of oral Vitamin D3 (cholecalciferol) capsules administered every two weeks for the duration of the study. The dose is designed to raise and maintain adequate serum 25-hydroxyvitamin D levels. Participants will receive the active supplement under supervised distribution, and adherence will be monitored through supplement logs and follow-up visits

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: 1Placebo comparator 1 intervention
Group B: 2Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Name: Change in ESR Unit: mm/hr

Standard Westergren method

Time frame
Baseline and week 12
2

Name: Change in CRP Unit: mg/L

Measured by immunoturbidimetry

Time frame
Baseline to 12 weeks
3

Name: Change in serum IL-6 Unit: pg/mL

Measured using ELISA

Time frame
Baseline to 12 weeks
4

Change in fecal calprotectin concentration Unit: µg/g

Fecal calprotectin measured using quantitative ELISA.

Time frame
Baseline and 12 weeks

Secondary outcomes

1

Name: Change in serum 25-hydroxyvitamin D (25-OH Vitamin D) levels Unit: ng/mL

Serum 25-OH Vitamin D levels will be measured using chemiluminescent immunoassay

Time frame
Baseline and 12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.